A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

Summary

Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight. In this study, the concentration of NNC0519-0130 in the blood will be measured and its safety will be evaluated. The participants will either get NNC0519-0130 or placebo (a "dummy" substance), which treatment the participants get is decided by chance. This study will test up to 7 different doses of NNC0519-0130 and will last for about 28 weeks.

Timeline

Start

2025-05-26

Primary completion

2026-01-28

Completion

2026-01-28

Drugs

Indications